Current concepts in multiple sclerosis therapy

References

• VasconcelosCCAurençãoJCThulerLCCamargoSAlvarengaMPAlvarengaRMPrognostic factors associated with long-term disability and secondary progression in patients with multiple sclerosisMult Scler Relat Disord20168273427456871
   PubMed Web of Science ®Google Scholar
• LeocaniLRoccaMAComiGMRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosisCur Opin Neurol201629243253
   Web of Science ®Google Scholar
• GiovannoniGMultiple sclerosis should be treated using a step-down strategy rather than a step-up strategy – yesMult Scler2016221397140027279588
   PubMed Web of Science ®Google Scholar
• NaismithRTMultiple sclerosis should be treated using a step-down strategy rather than a step-up strategy – noMult Scler2016221400140227279590
   PubMed Web of Science ®Google Scholar
• CzłonkowskaASmolińskiŁLitwinTSevere disease exacerbations in patients with multiple sclerosis after discontinuing fingolimodNeurol Neurochir Pol20175115616228209440
   PubMed Web of Science ®Google Scholar
• FagiusJFeresiadouALarssonEMBurmanJDiscontinuation of disease modifying treatments in middle aged multiple sclerosis patients: first line drugs vs natalizumabMult Scler Relat Disord201712828728283113
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multi-center, randomized, double-blind, placebo-controlled trialNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol1996392852948602746
   PubMed Web of Science ®Google Scholar
• CalabresiPAKieseierBCArnoldDLPegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyLancet Neurol20141365766524794721
   PubMed Web of Science ®Google Scholar
• EbersGCRandomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisLancet1998352149815049820297
   PubMed Web of Science ®Google Scholar
• MarkowitzCEInterferon-beta: mechanism of action and dosing issuesNeurology200768S8S1117562848
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trialNeurology199545126812767617181
   PubMed Web of Science ®Google Scholar
• BroadleySABarnettMHBoggildMTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective – part 1: historical and established therapiesJ Clin Neurosci2014211835184624993135
   PubMed Web of Science ®Google Scholar
• RackeMKLovett-RackeAEGlatiramer acetate treatment of multiple sclerosis: an immunological perspectiveJ Immunol20111861887189021289312
   PubMed Web of Science ®Google Scholar
• SheridanJPZhangYRiesterKIntermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosisMult Scler2011171441144821807759
   PubMed Web of Science ®Google Scholar
• MartinJFPerryJSJakheteNRWangXBielekovaBAn IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56bright NK cellsJ Immunol20101851311132020543101
   PubMed Web of Science ®Google Scholar
• KapposLWiendlHSelmajKDaclizumab HYP versus interferon beta-1a in relapsing multiple sclerosisN Engl J Med20153731418142826444729
   PubMed Web of Science ®Google Scholar
• GoldRGiovannoniGSelmajKDaclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialLancet20133812167217523562009
   PubMed Web of Science ®Google Scholar
• KapposLHavrdovaEGiovannoniGNo evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE studyMult Scler Epub2016121
   Web of Science ®Google Scholar
• GoldRRadueEWGiovannoniGSafety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension studyBMC Neurol20161611727461166
   PubMed Web of Science ®Google Scholar
• KapposLO’ConnorPRadueEWLong-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trialNeurology2015841582159125795646
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med201036240241520089954
   PubMed Web of Science ®Google Scholar
• KarlssonGFrancisGKorenGPregnancy outcomes in the clinical development program of fingolimod in multiple sclerosisNeurology20148267468024463630
   PubMed Web of Science ®Google Scholar
• PilzGHarrerAWipflerPTumefactive MS lesions under fingolimod: a case report and literature reviewNeurology2013811654165824097813
   PubMed Web of Science ®Google Scholar
• Bar-OrAPachnerAMenguy-VacheronFKaplanJWiendlHTeriflunomide and its mechanism of action in multiple sclerosisDrugs20147465967424740824
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med20113651293130321991951
   PubMed Web of Science ®Google Scholar
• ConfavreuxCO’ConnorPComiGOral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Neurol20141324725624461574
   PubMed Web of Science ®Google Scholar
• O’ConnorPComiGFreedmanMSLong-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO studyNeurology20168692093026865517
   PubMed Web of Science ®Google Scholar
• HeDZhangCZhaoXTeriflunomide for multiple sclerosisCochrane Database Syst Rev20163CD00988227003123
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med20123671098110722992073
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med20123671087109722992072
   PubMed Web of Science ®Google Scholar
• GoldRPhillipsJTHavrdovaEDelayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experienceNeurol Ther201549310426662361
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med201036241642620089960
   PubMed Web of Science ®Google Scholar
• RiceGPFilippiMComiGCladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trialNeurology2000541145115510720289
   PubMed Web of Science ®Google Scholar
• PakpoorJDisantoGAltmannDRNo evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineNeurol Neuroimmunol Neuroinflamm20152e15826468472
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med200635489991016510744
   PubMed Web of Science ®Google Scholar
• RiceGPHartungHPCalabresiPAAnti-α4 integrin therapy for multiple sclerosis: mechanisms and rationaleNeurology2005641336134215851719
   PubMed Web of Science ®Google Scholar
• PlavinaTSubramanyamMBloomgrenGAnti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathyAnn Neurol20147680281225273271
   PubMed Web of Science ®Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med20123661870188022591293
   PubMed Web of Science ®Google Scholar
• TanILMcArthurJCCliffordDBMajorEONathAImmune reconstitution inflammatory syndrome in natalizumab-associated PMLNeurology2011771061106721832229
   PubMed Web of Science ®Google Scholar
• FoxRJCreeBAde SezeJMS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption studyNeurology2014821491149824682966
   PubMed Web of Science ®Google Scholar
• JokubaitisVGLiVKalincikTFingolimod after natalizumab and the risk of short-term relapseNeurology2014821204121124610329
   PubMed Web of Science ®Google Scholar
• CalabresiPAGiovannoniGConfavreuxCThe incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELNeurology2007691391140317761550
   PubMed Web of Science ®Google Scholar
• RyersonLZFrohmanTCFoleyJExtended interval dosing of natalizumab in multiple sclerosisJ Neurol Neurosurg Psychiatry20168788588926917698
   PubMed Web of Science ®Google Scholar
• ColesAJCompstonDASelmajKWAlemtuzumab vs. interferon beta-1a in early multiple sclerosisN Engl J Med20083591786180118946064
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialLancet20123801829183923122650
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet20123801819182823122652
   PubMed Web of Science ®Google Scholar
• FreedmanMSRushCASevere, highly active, or aggressive multiple sclerosisContinuum (Minneap Minn)20162276178427261681
   PubMedGoogle Scholar
• WillisMDHardingKEPickersgillTPAlemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohortMult Scler2016221215122326514979
   PubMed Web of Science ®Google Scholar
• HauserSLThe Charcot Lecture –beating MS: a story of B cells, with twists and turnsMult Scler20152182125480864
   PubMed Web of Science ®Google Scholar
• HowellOWReevesCANicholasRMeningeal inflammation is widespread and linked to cortical pathology in multiple sclerosisBrain20111342755277121840891
   PubMed Web of Science ®Google Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med200835867668818272891
   PubMed Web of Science ®Google Scholar
• MontalbanXHauserSLKapposLOcrelizumab versus placebo in primary progressive multiple sclerosisN Engl J Med201737620922028002688
   PubMed Web of Science ®Google Scholar
• HauserSLBar-OrAComiGOcrelizumab versus interferon beta-1a in relapsing multiple sclerosisN Engl J Med201737622123428002679
   PubMed Web of Science ®Google Scholar
• KapposLLiDCalabresiPAOcrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multi-centre trialLancet20113781779178722047971
   PubMed Web of Science ®Google Scholar
• SørensenPSBlinkenbergMThe potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospectsTher Adv Neuro Disord201694452
   PubMed Web of Science ®Google Scholar
• HawkerKO’ConnorPFreedmanMSRituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialAnn Neurol20096646047119847908
   PubMed Web of Science ®Google Scholar
• BurtRKBalabanovRHanXAssociation of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosisJAMA201531327528425602998
   PubMed Web of Science ®Google Scholar
• ShevchenkoJLKuznetsovANIonovaTILong-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectivesAnn Hematol2015941149115725711670
   PubMed Web of Science ®Google Scholar
• BurmanJIacobaeusESvenningssonAAutologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experienceJ Neurol Neurosurg Psychiatry2014851116112124554104
   PubMed Web of Science ®Google Scholar
• NashRAHuttonGJRackeMKHigh-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MSNeurology20178884285228148635
   PubMed Web of Science ®Google Scholar
• SaccardiRKozakTBocelli-TyndallCAutologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party databaseMult Scler20061281482317263012
   PubMed Web of Science ®Google Scholar
• MuraroPAPasquiniMAtkinsHLLong-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosisJAMA Neurol20177445946928241268
   PubMed Web of Science ®Google Scholar
• MancardiGLSormaniMPGualandiFAutologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trialNeurology20158498198825672923
   PubMed Web of Science ®Google Scholar
• SaccardiRFreedmanMSSormaniMPA prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paperMult Scler20121882583422383228
   PubMed Web of Science ®Google Scholar
• MartinCLPhillipsBAKilpatrickTJGait and balance impairment in early multiple sclerosis in the absence of clinical disabilityMult Scler20061262062817086909
   PubMed Web of Science ®Google Scholar
• SimmonsRDTribeKLMcDonaldEALiving with multiple sclerosis: longitudinal changes in employment and the importance of symptom managementJ Neurol201025792693620084515
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTRKruppLBSustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialLancet200937373273819249634
   PubMed Web of Science ®Google Scholar
• MacdonellRNagelsGLaplaudDAImproved patient-reported health impact of multiple sclerosis: the ENABLE study of PR-fampridineMult Scler20162294495426447066
   PubMed Web of Science ®Google Scholar
• Otero-RomeroSSastre-GarrigaJComiGPharmacological management of spasticity in multiple sclerosis: systematic review and consensus paperMult Scler2016221386139627207462
   PubMed Web of Science ®Google Scholar
• FlacheneckerPHenzeTZettlUKNabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice: results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticityEur Neurol20147127127924525548
   PubMed Web of Science ®Google Scholar
• KesselringJBeerSSymptomatic therapy and neurorehabilitation in multiple sclerosisLancet Neurol2005464365216168933
   PubMed Web of Science ®Google Scholar
• PucciEBranãsPD’AmicoRGiulianiGSolariATausCAmantadine for fatigue in multiple sclerosisCochrane Database Syst Rev200714CD002818
   Google Scholar
• National Institute for Health and Care ExcellenceFatigue in Multiple Sclerosis: ModafinilLondonNICE2013
   Google Scholar
• ChiaravallotiNDMooreNBNikelshpurOMDeLucaJAn RCT to treat learning impairment in multiple sclerosis: the MEMREHAB trialNeurology2013812066207224212393
   PubMed Web of Science ®Google Scholar
• BonavitaSSaccoRCorte DellaMComputer-aided cognitive rehabilitation improves cognitive performances and induces brain functional connectivity changes in relapsing remitting multiple sclerosis patients: an exploratory studyJ Neurol20152629110025308631
   PubMed Web of Science ®Google Scholar
• FeinsteinAMagalhaesSRichardJFAudetBMooreCThe link between multiple sclerosis and depressionNat Rev Neurol20141050751725112509
   PubMed Web of Science ®Google Scholar
• DalgasUSlothMStenagerEThe effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literatureEur J Neurol20152244345625327395
   PubMed Web of Science ®Google Scholar
• Van Der WaltASungSSpelmanTA double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremorNeurology201279929922753445
   PubMed Web of Science ®Google Scholar
• XieTBernardJWarnkePPost subthalamic area deep brain stimulation for tremors: a mini-reviewTransl Neurodegener201212023210767
   PubMedGoogle Scholar
• KalbRCIntimacy and Sexuality in MSNew YorkNational Multiple Sclerosis Society2012
   Google Scholar
• FowlerCJMillerJRShariefMKHussainIFStecherVJSweeneyMA double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosisJ Neurol Neurosurg Psychiatry20057670070515834030
   PubMed Web of Science ®Google Scholar
• WattjesMPVennegoorASteenwijkMDMRI pattern in asymptomatic natalizumab-associated PMLJ Neurol Neurosurg Psychiatry20148679379825205744
   PubMed Web of Science ®Google Scholar
• SchwabNSchneider-HohendorfTPignoletBPML risk stratification using anti-JCV antibody index and L-selectinMult Scler2016221048106026432858
   PubMed Web of Science ®Google Scholar
• FreedmanMSSelchenDArnoldDLTreatment optimization in MS: Canadian MS Working Group updated recommendationsCan J Neurol Sci20134030732323603165
   PubMed Web of Science ®Google Scholar
• RíoJRoviraATintorèMDisability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patientsMult Scler Epub201731
   Google Scholar
• KapposLWeinshenkerBPozzilliCInterferon beta-1b in secondary progressive MS: a combined analysis of the two trialsNeurology2004631779178715557490
   PubMed Web of Science ®Google Scholar
• GoodinDSRederATEbersGCSurvival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trialNeurology2012781315132222496198
   PubMed Web of Science ®Google Scholar
• AtkinsHLBowmanMAllanDImmunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trialLancet201638857658527291994
   PubMed Web of Science ®Google Scholar
• BarkhofFBrain atrophy measurements should be used to guide therapy monitoring in MS – noMult Scler2016221524152627335096
   PubMed Web of Science ®Google Scholar